|
|
Post by cjm18 on May 17, 2022 7:19:32 GMT -5
David Kendall works for them. Happy to see Mnkd is still dedicated to endocrinology. Why are there sales milestones. What does Kendall do for them? I don’t see him on their website. Senior global medical advisor |
|
|
|
Post by cretin11 on May 17, 2022 7:22:23 GMT -5
Curious as to how this will change the job of MannKind’s sales personnel. It can augment the offering and adds a tool for managing the disease, though it weakens the “needle-free” angle and might add complexity (and cost?) to the sales pitch. Will it be a net plus or minus for Afrezza, I suppose the numbers will answer that question soon enough.
The opinion I’m eager to hear is Bill’s. Sports, hopefully you’ll be able to share with us his take at some point.
|
|
|
|
Post by awesomo on May 17, 2022 7:22:30 GMT -5
|
|
|
|
Post by cretin11 on May 17, 2022 7:29:36 GMT -5
What does Kendall do for them? I don’t see him on their website. Senior global medical advisor Correct, he left his Chief Medical Officer position at MannKind almost two years ago to take his current job with Zealand. |
|
|
|
Post by hopingandwilling on May 17, 2022 7:35:34 GMT -5
V-Go was approved by the FDA 12 years ago---appears the product has been highly unsuccessful. Couldn't MNKD have found a better product to buy?
|
|
|
|
Post by awesomo on May 17, 2022 7:37:23 GMT -5
V-Go was approved by the FDA 12 years ago---appears the product has been highly unsuccessful. Couldn't MNKD have found a better product to buy? There lies the crux, if the product was doing well, the original company wouldn't sell it barring some massive overpay. |
|
|
|
Post by sayhey24 on May 17, 2022 7:40:20 GMT -5
David Kendall works for them. Happy to see Mnkd is still dedicated to endocrinology. Why are there sales milestones. What does Kendall do for them? I don’t see him on their website. Dr. David Kendall is a senior global medical advisor at Zealand Pharma, aka a consultant. It would be interesting if Dave was now back in the picture now that Mounjaro was approved last Friday. Not saying they are related but I find it interesting. |
|
|
|
Post by awesomo on May 17, 2022 7:48:47 GMT -5
Breaking down the financials more...
Zealand's V-Go revenue in 2020 was $22.85M from the sales period of April 2 to the EoY (after acquisition), so those numbers are from 9 months.
Total revenue for Zealand in 2021 was $26.07M, and those include a new product for them, Zegalogue (commercially available in June 2021), as well as a full 12 months for V-Go with their full marketing and sales effort.
It is pretty clear why they unloaded V-Go so quickly.
|
|
|
|
Post by sayhey24 on May 17, 2022 8:00:22 GMT -5
V-Go was approved by the FDA 12 years ago---appears the product has been highly unsuccessful. Couldn't MNKD have found a better product to buy? There lies the crux, if the product was doing well, the original company wouldn't sell it barring some massive overpay. The question is what are they going to do with it? If Dave Kendall thinks it could be the patch pump Al talked about for the T1s in combination with afrezza maybe Mike just bought a winner. Of course there would need to be trials but I would assume Dave has already done some preliminary pilots. If Mike is just buying it to buy things I really think the time and money could be much better spent putting a head-to-head trial together against Mounjaro. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on May 17, 2022 8:05:45 GMT -5
V-Go has been on the market since 2012. In research, V-Go was found to be as effective as multiple daily injections of insulin in controlling blood sugar and lowering the amount of total amount of insulin needed per day. 2021 Revs $141K?? Definitely a head scratcher!! Will T2's and maybe T1's be confident in using the patch AND Inhaling insulin??? |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on May 17, 2022 8:09:33 GMT -5
What an exciting acquisition! MannKind has once again demonstrated a high level of self efficacy. Self efficacy is the belief an entity holds regarding their ability to affect a given circumstance or experience. It’s the belief that challenges are experiences that ought to be mastered rather than avoided—a belief that one has the power to affect the future through their choices. A high self efficacy manifests during challenging times—a reoccurring theme we have been witnessing as the MannKind Story unfolds. Another confident and complimentary decision executed by the Company to further expand the endocrine business, add tools to the sales force, increase revenue, and give a synergistic basal delivering medical device that can be paired nicely with Afrezza. I’m looking forward to hearing MannKind’s strategic long term vision with this new acquisition. Yes mango....this is exciting (your words). MNKD spends $10M+ for a product that has been on the market since 2011 and the previous owner is dumping it after 2 years. Can't wait to hear Mike's spin. |
|
|
|
Post by hellodolly on May 17, 2022 8:09:35 GMT -5
V-Go has been on the market since 2012. In research, V-Go was found to be as effective as multiple daily injections of insulin in controlling blood sugar and lowering the amount of total amount of insulin needed per day. 2021 Revs $141K?? Definitely a head scratcher!! Will T2's and maybe T1's be confident in using the patch AND Inhaling insulin??? 2021 26M revenue. 1,000,000 DKK equals 141K USD. 184,000,000 DKK X .141 = $26M USD |
|
|
|
Post by Clement on May 17, 2022 8:10:01 GMT -5
If a diabetic wants to use a combination of V-GO for basal and Afrezza for mealtime, what would be the best product to load into the V-GO device?
|
|
|
|
Post by Clement on May 17, 2022 8:10:54 GMT -5
V-Go has been on the market since 2012. In research, V-Go was found to be as effective as multiple daily injections of insulin in controlling blood sugar and lowering the amount of total amount of insulin needed per day. 2021 Revs $141K?? Definitely a head scratcher!! Will T2's and maybe T1's be confident in using the patch AND Inhaling insulin??? Revs USD 22.8 million in 2020 (HD said that one million DKK = $141K USD. Use that fact to calculate the conversion of Revs fromm DKK to USD.) |
|
|
|
Post by peppy on May 17, 2022 8:16:06 GMT -5
There lies the crux, if the product was doing well, the original company wouldn't sell it barring some massive overpay. The question is what are they going to do with it? If Dave Kendall thinks it could be the patch pump Al talked about for the T1s in combination with afrezza maybe Mike just bought a winner. Of course there would need to be trials but I would assume Dave has already done some preliminary pilots. If Mike is just buying it to buy things I really think the time and money could be much better spent putting a head-to-head trial together against Mounjaro. So it is a refillable patch pump that runs at three rates and 2 unit boluses can be given.   |
|
